Hormone-Encapsulating Hydrogel Microspheres Through UV Crosslinking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hormone therapies face challenges such as inconsistent dosage delivery, adverse effects, and poor compliance due to methods like pills, patches, and creams, while subcutaneous hydrogel microspheres for controlled drug release have stability and bioavailability issues.
Innovation Solution
A method for producing crosslinked methacrylate hyaluronic acid (MHA) polymer microbeads encapsulating hormones, involving an uncrosslinked MHA polymer precursor solution encapsulating a hormone, followed by crosslinking with ultraviolet light and removing the outer alginate shell to form stable hydrogel microspheres.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If subcutaneous hydrogel microspheres are used for controlled drug release, then dosage consistency and patient compliance are improved, but stability and bioavailability issues worsen
Solution Approach 1:
The patent uses a composite material system consisting of methacrylate hyaluronic acid (MHA) polymer combined with alginate shell. The MHA provides controlled drug release properties while the alginate shell enhances stability during storage and delivery. This composite structure resolves the contradiction by combining materials with complementary properties to achieve both dosage consistency and stability.
Solution Approach 2:
The patent employs photopolymerization crosslinking to change the physical-chemical parameters of the hydrogel matrix. By controlling the crosslinking density and network structure through UV irradiation, the patent optimizes both the stability of the microsphere composition and the controlled release characteristics, thereby achieving dosage consistency without compromising stability.
2Ease of operation
If traditional hormone therapies (pills, patches, creams) are used, then ease of administration is improved, but dosage consistency and therapeutic effectiveness worsen
Solution Approach 1:
The patent replaces traditional mechanical delivery systems (pills requiring swallowing, patches requiring skin application) with an injectable hydrogel microsphere system. This substitution maintains ease of administration through simple injection while achieving reliable dosage consistency through the controlled release mechanism of the hydrogel matrix, eliminating the dosage variability inherent in traditional therapies.
3Reliability
If frequent hormone injections are administered, then therapeutic effectiveness is improved, but patient compliance and convenience worsen
Solution Approach 1:
The patent incorporates the hormone therapeutic agent into the hydrogel microsphere matrix in advance, creating a pre-formulated controlled release system. This preliminary action allows the drug to be delivered in a single injection that provides sustained therapeutic effectiveness over an extended period, eliminating the need for frequent repeat injections and thereby improving patient compliance while maintaining therapeutic effectiveness.
4Duration of action of moving object
If hydrogel formulation is used for hormone delivery, then controlled release is improved, but absorption and bioavailability issues worsen
Solution Approach 1:
The patent utilizes the porous network structure of the crosslinked MHA hydrogel matrix to control drug release. The porosity of the hydrogel allows for controlled diffusion of the hormone therapeutic agent, ensuring consistent bioavailability over time. The crosslinked structure maintains stable pore sizes that regulate drug release kinetics, resolving the contradiction between extended controlled release duration and reliable bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a stable, extended-release hydrogel formulation with improved bioavailability and compliance, offering consistent hormone delivery with fewer invasive procedures and reduced doctor visits.
Implementation Method 1
Ultraviolet light is applied to the uncrosslinked MHA polymer precursor compound in the core shell microparticle liquid core. A crosslinked MHA polymer microparticle encapsulating the hormone is generated.
Data Source
AI summary
A method for encapsulating a hormone in a hydrogel is described. The method includes providing an uncrosslinked methacrylate hyaluronic acid (MHA) polymer precursor solution that includes the hormone, MHA, sodium hyaluronate, and a divalent cation. An alginate bath is provided that includes alginate and water. Droplets of the uncrosslinked MHA polymer precursor solution are extruded into the alginate bath to yield a plurality of core shell microparticles that include an outer alginate shell and a liquid core of uncrosslinked MHA polymer precursor solution. Ultraviolet light is applied to the uncrosslinked MHA polymer precursor compound in the core shell microparticle liquid core. A crosslinked MHA polymer microparticle encapsulating the hormone is generated that includes the outer alginate shell and an inner core of the crosslinked MHA polymer. The method removes the outer alginate shell to yield the hydrogel encapsulating the hormone.